Last reviewed · How we verify
adding Certican to therapy
At a glance
| Generic name | adding Certican to therapy |
|---|---|
| Sponsor | Rabin Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (PHASE2)
- Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |